Format

Send to

Choose Destination
J Occup Environ Med. 2011 Apr;53(4):405-14. doi: 10.1097/JOM.0b013e31820fd1c9.

Economic impact to employers of treatment options for cardiac arrhythmias in the US health system.

Author information

1
HCMS Group LLC, Cheyenne, WY, USA. nathan_kleinman@hcmsgroup.com

Abstract

OBJECTIVE:

To measure relative employer-sponsored postablation costs for cardiac arrhythmias (CA), specifically atrial fibrillation (AF).

METHODS:

Regression-Controlled Employee/Spouse Database study (2001 to 2008) comparing CA patients with and without ablation and AF patients with and without ablation. Regression-adjusted monthly medical, pharmacy, sick leave, and short-term disability costs were calculated 11 months before index to 36 months after index (first ablation date or average date for nonablation patients). Relative pre/postindex comparisons between ablation and nonablation cohorts were calculated and time until ablation procedure cost recovery extrapolated.

RESULTS:

Few CA (280 of 11,291; 2.48%) and AF (93 of 3062; 3.04%) patients received ablation. Ablation cohorts cost less than nonablation cohorts postablation. Estimated total ablation-period costs were recovered 38 to 50 months postablation, including employee absence payment recovery within 18 months.

CONCLUSION:

Current ablation use in employer-sponsored health plans may improve health care and absence costs over time.

PMID:
21407098
DOI:
10.1097/JOM.0b013e31820fd1c9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center